Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2007-02-06
2007-02-06
Mertz, Prema (Department: 1646)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S046000, C530S350000
Reexamination Certificate
active
11048364
ABSTRACT:
The present invention provides storage stable dry powder compositions of IL-4R. The powder compositions demonstrate superior chemical and physical stability over their solution counterparts, particularly upon storage under varying conditions of temperature and humidity. Moreover, the powders, as prepared, possess good aerosol properties, which are maintained upon storage.
REFERENCES:
patent: 5599905 (1997-02-01), Mosley et al.
patent: 5767067 (1998-06-01), Arpaia et al.
patent: 5856296 (1999-01-01), Mosley et al.
patent: 6063371 (2000-05-01), Maliszewski et al.
patent: 6210661 (2001-04-01), Enssle et al.
patent: 6328954 (2001-12-01), Enssle et al.
patent: 6582728 (2003-06-01), Platz et al.
patent: 01/08708 (2001-02-01), None
patent: WO 0108708 (2001-02-01), None
patent: 01/62272 (2001-08-01), None
patent: WO 0162272 (2001-08-01), None
Borish et al., “Interleukin-4 Receptor in Moderate Atopic Asthma”, Am. J. Respir. Crit. Care Med., 160(6):1816-1823.
Chen et al., “CD4+T Lymphocyte Modulation of Ozone-Induced Murine Pulmonary Inflammation”, Am. J. Respir. Cell Mol. Biol., 12(4):396-403.
Cohn et al., “Th2-Induced Airway Mucus Production is Dependent on IL-4R alpha, But Not on Eosinophils”, J. Immunol., 162(10):6178-6183.
Lange, “Interleukin 4 Receptor Immunex Corp.”, Current Opinion in Cardiovascular, Pulmonary & Renal Investigational Drug 1999, 1(4):526-531, abstract.
NOSSAL, Nature, 162:36-37, (1948).
Sangwan et al., “Aerosolized Protein Delivery in Asthma; Gamma Camera Analysis of Regional Deposition and Perfusion”, J. Aerosol Med., 14(2):185-195.
Cohn et al., “Th2-Induced Airway Mucus Production is Dependent on IL-4R alpha. But Not on Eosinophils,” J. Immunol, vol. 162, (No. 10), p. 6178-83.
Borish et al., “Interleukin-4 Receptor in Moderate Atopic Asthma,” Am J Respir Crit Care Med. vol. 160 (No. 6), p. 1816-23.
Chen et al., “CD4+ T Lymphocyte Modulation of Ozone-Induced Murine Pulmonary Inflammation,” Am J Respir Cell Mol Biol. vol. 12 (No. 4), p. 396-403.
Sangwan et al., “Aerosolized Protein Delivery in Asthma: Gamma Camera Analysis of Regional Deposition and Perfusion,” J. Aerosol Med. vol. 14 (No. 2), p. 185-95.
Robert Lange, “Interleukin 4 Receptor Internex Corp.” Databse CA Online Chem. Abstract Serv., Columbus, Ohio, US; retrieved from STN Database accession No. 132:220921 CA XP002216866. Current Opinion in Cardiovascular, Pulmonary & Renal Investigational Drug 1999. 1(4), p. 526-531. abstract.
Cabot Kirsten
Gong David
Hastedt Jayne
Hester Dennis
Mertz Prema
Nektar Therapeutics
Wilson Mark A.
LandOfFree
Storage stable powder compositions of interleukin-4 receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Storage stable powder compositions of interleukin-4 receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Storage stable powder compositions of interleukin-4 receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3833146